Cell>Point reports promising findings for 99mTc-EC-G

04/10/2013 | AuntMinnie.com (free registration)

Radiopharmaceutical firm Cell>Point said findings from Phase I and IIa trials were promising for its technetium-99m-labeled ethylenedicysteine-glucosamine, an imaging agent used in diagnosing coronary artery disease. The company is planning a Phase IIb study to assess the diagnostic accuracy of the agent in identifying ischemia in patients at rest who have coronary artery disease.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY